Columbia researchers report precise base edits in early human embryos, targeting PCSK9 and HBG. Experts warn mosaicism and long‑term safety risks remain.

Justice Department files show Jeffrey Epstein deposited sperm with California Cryobank and signed a 2016 contract leaving the samples to his estate; the material’s whereabouts remain unclear.

A Baylor‑led consortium's AllFaith Benchmark finds major language models often omit religious perspectives in ethics answers and show conversion biases. The work is open‑sourced for developers and scholars.

Updated CHORD trial numbers presented in Seoul suggest most children with otoferlin‑related deafness gained meaningful hearing after Otarmeni treatment. The therapy was FDA‑cleared in April.

Early trial data show amivantamab shrank—and in some patients erased—tumors in treatment‑resistant head and neck cancer, with results set for ASCO on Sunday. Investigators call the responses striking but preliminary.

Columbia researchers identify SIRT1 as a driver of treatment‑resistant neuroendocrine prostate cancer and show blocking it halts tumors in mice.

DFS told banks, insurers and crypto firms to tighten authentication, accelerate patching and test backups amid concerns that frontier AI and geopolitical shocks could raise cyber risk.

John Hill has been named director of Brookhaven National Laboratory as the Upton campus pivots from RHIC operations to the Electron‑Ion Collider and major upgrades. He'll oversee the lab's $900M budget and 3,000 staff.

Mastercard won a New York BitLicense on May 27, giving it regulated footing to expand stablecoin and tokenized‑payment services under state supervision.

Cette AI founder Michael LaFave alleges Voya Financial accessed his devices, stole code and tracked him, a New York lawsuit says.

Chicago's Architect is pushing exchange‑traded futures on GPU and DRAM prices, setting up competition with CME and ICE. The move could make compute costs a tradable asset.

An experimental drug called bepirovirsen produced durable 'functional cures' in roughly 20% of patients in large trials, offering a potential finite therapy for chronic hepatitis B.

Modelers have removed the extreme RCP8.5/SSP5‑8.5 marker from the CMIP7 design; the revision narrows the upper‑end of projections but still leaves large warming and financial risk.